• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ICON Taps Ovation for New Lifecycle Sciences Business Group

ICON Taps Ovation for New Lifecycle Sciences Business Group

June 25, 2007
CenterWatch Staff

Dublin-based ICON Clinical has established a new business unit called its lifecycle sciences group, focusing specifically on outcomes research and economic analysis services. The news was announced during the Drug Information Association (DIA) 43rd Annual Meeting in Atlanta. The group will work with stakeholders across the client organization in area such as clinical development, but also with sales and marketing, medical affairs and strategic development groups—units where most contract research organizations (CROs) have less interaction with.

The core of the group will be Illinois-based Ovation, which ICON acquired in July 2006. The company, now a part of ICON’s clinical research division, conducts prospective pharmacoeconomic and quality-of-life analysis, disease and product registries, and health outcomes research.

Originally dubbed Ovation Healthcare Research, the company was founded in 1990. Ovation’s founder and former president Jeff Trotter, has been promoted to senior vice president of ICON's new lifecycle sciences group.

“This time last year, [Ovation] became pretty much the corner stone of ICON’s late stage business, but one of the things that we’ve done in evolving to this lifecycle sciences group is help everyone recognize that what we do isn’t just in the post approval realm. A lot of what we do starts as early as phase II up to through approval and beyond. That is kind of where the concept of lifecycle sciences came from,” said Trotter.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing